{"id":486,"date":"2019-12-13T14:21:15","date_gmt":"2019-12-13T14:21:15","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=486"},"modified":"2019-12-16T07:10:58","modified_gmt":"2019-12-16T07:10:58","slug":"speaker-interview-with-petter-bjorquist-for-4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress-2","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/speaker-interview-with-petter-bjorquist-for-4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress-2\/","title":{"rendered":"Speaker Interview with Karin Jennbacken for 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies &#038; Regenerative Medicine Congress"},"content":{"rendered":"\n<p>London, December 13 \u2013 MarketsandMarkets interviewed <strong>Karin Jennbacken<\/strong>, Team Leader, Heart Failure in vitro team, AstraZeneca regarding <strong>4<\/strong><sup><strong>th<\/strong><\/sup><strong> Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies &amp; Regenerative Medicine Congress<\/strong> taking place on 10-11 March 2020 in London \u2013 UK. Dr Jennbacken\u2019s team is responsible for target discovery and early development of therapeutics for treatment of patients with cardiovascular disease.<\/p>\n\n\n\n<p>Q. <strong>What is the most trending areas of cellular therapies currently?<\/strong> <\/p>\n\n\n\n<p>A. Cardiac therapies using pluripotent stem cells is where most of the researches are going on.<\/p>\n\n\n\n<p>Q. <strong>What are the recent developments and technological advancements?<\/strong> <\/p>\n\n\n\n<p>Making universal stem cells is the most promising development in this field currently.<\/p>\n\n\n\n<p><strong>Q. What are the key take away points from your presentation? <\/strong><\/p>\n\n\n\n<p>A. The attendees would get to know about the key opportunities with PSC derived cardiac cells for patients with heart failure<\/p>\n\n\n\n<p>Q. <strong>Hope you had a chance to go through the attached agenda. Please share your feedback on the same, also do let us know which community would be most benefitted by the agenda<\/strong>. <\/p>\n\n\n\n<p>A. I am looking forward to the meeting and explore!<\/p>\n\n\n\n<p><strong>Karin Jennbacken<\/strong> will present on &#8216;Opportunity and challenges in cardiac cell therapy&#8217; at the event.<\/p>\n\n\n\n<p>The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register &#8211; <a href=\"https:\/\/bit.ly\/2qKzuSC\" target=\"_blank\" rel=\"noopener\"><strong>https:\/\/bit.ly\/2qKzuSC<\/strong><\/a><strong> <\/strong><\/p>\n\n\n\n<p>For more inquiries contact Suraj Waghmare, Marketing Executive on <strong><a href=\"http:\/\/suraj.waghmare@marketsandmarkets.com\ufeff\">suraj.waghmare@marketsandmarkets.com<\/a><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" width=\"600\" height=\"170\" src=\"http:\/\/events.marketsandmarkets.com\/blog\/wp-content\/uploads\/2019\/12\/4th-BACT_600x170.jpg\" alt=\"https:\/\/events.marketsandmarkets.com\/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress\/\" class=\"wp-image-484\" srcset=\"https:\/\/events.marketsandmarkets.com\/blognew\/wp-content\/uploads\/2019\/12\/4th-BACT_600x170.jpg 600w, https:\/\/events.marketsandmarkets.com\/blognew\/wp-content\/uploads\/2019\/12\/4th-BACT_600x170-200x57.jpg 200w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>London, December 13 \u2013 MarketsandMarkets interviewed Karin Jennbacken, Team Leader, Heart Failure in vitro team, AstraZeneca regarding 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies &amp; Regenerative Medicine Congress taking place on 10-11 March 2020 in London \u2013 UK. Dr Jennbacken\u2019s team is responsible for target discovery and early development of therapeutics for treatment of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":487,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,5,2],"tags":[189,78,143,188],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/486"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=486"}],"version-history":[{"count":3,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/486\/revisions"}],"predecessor-version":[{"id":490,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/486\/revisions\/490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/487"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}